IPHA: Innate Pharma SA insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
10 institutions reported holding $354K of Innate Pharma SA on Form 13F (9 the quarter before). 3 opened a new position and 2 sold out. Shares held by institutions: +5%.
| Largest holders | Shares | Value |
|---|---|---|
| Lion Point Capital, LP | 81,151 | $149K |
| MORGAN STANLEY | 43,524 | $80K |
| SmartHarvest Portfolios, LLC | 23,750 | $44K |
| XTX Topco Ltd | 15,130 | $28K |
| CITADEL ADVISORS LLC | 12,441 | $23K |
| JANE STREET GROUP, LLC | 10,310 | $19K |
| RHUMBLINE ADVISERS | 4,719 | $9K |
| UBS Group AG | 1,363 | $3K |
| Farther Finance Advisors, LLC | 21 | $38 |
| GAMMA Investing LLC | 9 | $17 |
Clinical trial readouts
1 Phase 2 or 3 trials by Innate Pharma SA with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-06 (est.) | IPH5201 + durvalumab + standard chemotherapy | Non Small Cell Lung Cancer | Phase 2 | 70 | Recruiting | NCT05742607 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.